FDA Approves Ajovy for Migraine Prevention in Children and Adolescents
The FDA has approved Ajovy, a CGRP antagonist, for preventing episodic migraines in children and adolescents aged 6 to 17, offering a new targeted treatment option for young patients. that can help reduce migraine attacks and improve quality of life.
The U.S. Food and Drug Administration (FDA) has granted approval for the use of Ajovy (fremanezumab-vfrm) as a preventive treatment for episodic migraines in children and teenagers. This marks a significant advancement in pediatric migraine management, addressing a common yet often overlooked condition affecting approximately one in ten children and adolescents in the United States. Migraines in young individuals can lead to missed school days, difficulties with learning, and social challenges.
Ajovy is unique as it is the first medication in its class—a calcitonin gene-related peptide (CGRP) antagonist—approved for both pediatric and adult patients. It is suitable for children and teens aged 6 to 17 years who weigh at least 45 kilograms (99 pounds). The medication comes in a 225-mg/1.5-mL single-dose injection, which can be administered by healthcare professionals or self-injected at home by the patient or a caregiver using a prefilled autoinjector or syringe.
Jennifer McVige, M.D., from the DENT Neurologic Institute in Buffalo, New York, emphasized the impact of migraines on young patients, noting that an approved treatment offers new hope. She explained, "Pediatric migraine is a complex condition that can significantly influence a child's daily life, from school performance to emotional well-being. Having an FDA-approved option like Ajovy provides a targeted approach to prevention, helping to reduce migraine frequency and improve quality of life."
The approval was granted to Teva Pharmaceuticals, reflecting the company's commitment to expanding migraine treatment options.
More details about this approval can be found in the official announcement from Teva.
Source: https://medicalxpress.com/news/2025-08-fda-ajovy-migraine-children-teens.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Brain Tumor Gene Expression Database Accelerates Treatment Discovery
A groundbreaking genomic atlas of nervous system tumors offers new insights into tumor classification and potential targeted therapies, accelerating research and treatment development for brain and nerve cancers.
Obesity and Physical Activity as Factors Influencing Cancer Risk in Childhood Cancer Survivors
A recent study reveals that body weight and physical activity significantly influence the risk of secondary cancers in childhood cancer survivors, emphasizing the importance of lifestyle management in long-term survivorship care.
Understanding the Risks of Achilles Tendon Injuries
The Achilles tendon is vital for movement but highly susceptible to injuries like ruptures, especially in athletes. Learn about causes, treatment, and recovery options.